FLT3–TAZ Signaling Drives Drug Resistance in Blast Phase CML

Study Background and Research Question

Chronic myeloid leukemia (CML) is marked by the presence of the BCR::ABL1 fusion tyrosine kinase, which drives uncontrolled proliferation of myeloid cells. While BCR::ABL1 tyrosine kinase inhibitors (TKIs) have transformed CML into a manageable disease for most patients, a subset progresses to advanced stages, notably blast phase (BP-CML), where drug resistance and poor prognosis are common. Traditional therapeutic strategies focus on BCR::ABL1 kinase-dependent mechanisms of resistance, primarily managing point mutations within the kinase domain. However, resistance in BP-CML is increasingly recognized to involve kinase-independent pathways, creating a critical need for alternative therapeutic targets and prognostic markers. Shin et al. (2023) address this by investigating the role of FMS-like tyrosine kinase 3 (FLT3) in BP-CML drug resistance, expanding its relevance beyond acute myeloid leukemia (AML) into the context of CML progression and therapy resistance.

Key Innovation from the Reference Study

The central innovation of Shin et al.'s study lies in repositioning FLT3—not only as a hallmark of AML but also as a prognostic marker and actionable therapeutic target in BP-CML. The authors systematically demonstrate that FLT3 expression in CML cells activates a signaling cascade (FLT3–JAK–STAT3–TAZ–TEAD–CD36) which confers resistance to a broad spectrum of BCR::ABL1 TKIs, independent of known BCR::ABL1 mutations. This mechanistic insight highlights a previously underappreciated route to drug resistance and identifies a molecularly defined FLT3-positive BP-CML subgroup with distinct biological and clinical features. The work also validates therapeutic strategies that combine FLT3 inhibitors with existing TKI regimens, providing a rational basis for overcoming resistance in FLT3-positive cases.

Methods and Experimental Design Insights

To elucidate the role of FLT3 in BP-CML, Shin et al. adopted a multi-omics approach integrating cell line models, patient-derived samples, and in vivo studies:

• Generation of FLT3-expressing, TKI-resistant CML cell lines: The authors engineered CML cells to stably express FLT3 and characterized their resistance to multiple BCR::ABL1 TKIs.
• Patient cohort analysis: Serial and cross-sectional specimens from CML patients at various disease phases were analyzed for FLT3 expression and clinical correlations.
• Omics profiling: Transcriptomic and proteomic analyses were performed to delineate downstream pathways activated by FLT3, focusing on the JAK–STAT3–TAZ–TEAD–CD36 axis.
• In vivo validation: Mouse xenograft models of FLT3-positive BP-CML were employed to evaluate therapeutic interventions and to confirm the in vivo relevance of FLT3-driven resistance.
• Functional assays: Techniques such as FLT3 autophosphorylation inhibition assays and viability/apoptosis measurements were used to quantify drug responses.

This multifaceted design enabled the authors to connect molecular signaling events with phenotypic drug resistance, both in vitro and in vivo, and to substantiate therapeutic hypotheses in clinically relevant models.

Core Findings and Why They Matter

The study's core findings are as follows:

• FLT3 as a marker of drug resistance: FLT3 expression in BP-CML cells activates the FLT3–JAK–STAT3–TAZ–TEAD–CD36 pathway, driving resistance to BCR::ABL1 TKIs independently of BCR::ABL1 mutations (Shin et al., 2023).
• Distinct clinical subgroup: FLT3-positive BP-CML patients have a significantly worse prognosis compared to FLT3-negative counterparts, justifying their clinical stratification.
• Therapeutic synergy: Combined use of FLT3 inhibitors and BCR::ABL1 TKIs (or ponatinib monotherapy) effectively overcomes drug resistance in both patient-derived CML cells and mouse xenograft models, leading to increased apoptosis and tumor regression.
• Mechanistic independence: The resistance conferred by FLT3 operates independently of recurrent BCR::ABL1 kinase domain mutations, spotlighting the significance of targeting parallel signaling networks.

These insights are highly significant for both basic and translational research. They establish FLT3 as a cross-lineage driver of therapy resistance and suggest that diagnostic assessment of FLT3 status could inform prognosis and guide combination therapy strategies in advanced CML, much as is already practiced in AML. The demonstration of in vivo FLT3 inhibition in mouse xenograft models further supports the translational feasibility of these findings.

Comparison with Existing Internal Articles

While the literature on FLT3 has been dominated by its role in AML, internal resources such as Quizartinib (AC220): Optimizing FLT3 Inhibition in AML Research and Quizartinib (AC220): Selective FLT3 Inhibitor for AML Research emphasize the utility of Quizartinib in dissecting FLT3 signaling, resistance mechanisms, and high-sensitivity FLT3 autophosphorylation inhibition assays in AML models. These articles highlight Quizartinib's nanomolar potency, selectivity, and robust in vivo efficacy, which align well with the technical requirements outlined by Shin et al. for studying FLT3-driven resistance in CML. The reference study extends these principles to CML, demonstrating that workflows established in AML research—such as the use of FLT3 inhibitors to model resistance and therapeutic response—are directly transferable to BP-CML investigations, especially for functional and translational studies involving FLT3-ITD and wild-type variants.

Moreover, the internal article summarizing Shin et al. further contextualizes the impact of FLT3–TAZ signaling in the emergence of drug resistance and justifies the pursuit of combination therapies in BP-CML.

Limitations and Transferability

Despite its comprehensive design, the study by Shin et al. has limitations that should be considered. First, while the multi-omics and functional data strongly support a causal role for FLT3 in BP-CML resistance, the clinical cohort size for FLT3-positive cases remains relatively modest. This may limit the immediate generalizability of the prognostic findings and necessitates future large-scale validation. Second, although the in vivo experiments demonstrate proof-of-concept for the efficacy of FLT3 inhibition, the heterogeneity of patient-derived xenograft models and the potential for off-target effects or resistance evolution in clinical settings require further exploration. The study is also primarily focused on the blast phase, so applicability to earlier CML phases or other hematologic malignancies remains to be determined.

Protocol Parameters

• FLT3 expression analysis: Use immunoblotting or immunohistochemistry to assess FLT3 protein levels in CML models and patient specimens for subgroup classification.
• FLT3 autophosphorylation inhibition assay: Employ Quizartinib or other selective FLT3 inhibitors at low nanomolar concentrations (1–10 nM) to assess pathway blockade, in line with established AML research workflows.
• In vivo FLT3 inhibition in mouse xenograft models: Oral dosing regimens as low as 1 mg/kg Quizartinib have been reported to significantly inhibit FLT3 activity and tumor burden in FLT3-driven models, with plasma C_max achieved within 2 hours post-dosing according to the product information.
• Combination therapy protocols: Co-administration of BCR::ABL1 TKIs and FLT3 inhibitors should be guided by cell viability and apoptosis readouts, with dose optimization based on synergistic effects observed in vitro and in vivo.
• Resistance modeling: Introduce FLT3 expression into TKI-resistant CML cell lines to recapitulate clinical resistance mechanisms, as described by Shin et al.

Research Support Resources

Researchers aiming to explore FLT3-driven resistance mechanisms or to validate combination therapy approaches in CML or AML models can leverage selective FLT3 inhibitors with high potency and specificity. Quizartinib (AC220) (SKU A5793) is a well-characterized FLT3 inhibitor with nanomolar efficacy against both FLT3-ITD and wild-type forms, suitable for in vitro and in vivo studies of FLT3 signaling and drug resistance. Product specifications, including dosing and solubility guidelines, are available from APExBIO and can facilitate protocol design for advanced leukemia research workflows.